• Revolution Medicines began dosing patients in a global Phase 3 trial testing daraxonrasib with zoldonrasib in first-line metastatic RAS G12D pancreatic cancer.
• Prior results were already presented from an earlier clinical setting, showing antitumor activity with manageable safety in previously treated metastatic disease.
• The new study aims to confirm whether the regimen can outperform standard chemotherapy and support a potential shift in first-line treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9838951) on October 05, 2026, and is solely responsible for the information contained therein.